Takahiro Wakasaki

Dr. Takahiro Wakasaki

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2010 in Current Cancer Drug Targets
Verified
Journal Article
Closed access
PDF file
MMM. Masuda
M. Masuda
TWTakahiro Wakasaki
Takahiro Wakasaki
MSM. Suzui
M. Suzui
STS. Toh
S. Toh
AJA. K. Joe
A. K. Joe
IWI. B. Weinstein
I. B. Weinstein
Despite recent advancements in treatment modalities, the overall survival and quality of life of patients with head and neck squamous cell carcinoma (HNSCC) have not significantly improved over the past decade. With the increasing emergency of new biological agents, the development of novel treatment schemes based on cancer cell biology may be promising for this group of patients. We previously introduced the “oncogene addiction” concept as a rationale for molecular targeting in cancer therapy and prevention. In this context, an increasing number of preclinical studies have demonstrated that the Signal Transducers and Activators of transcription 3 (Stat3) transcription factor play critical roles in the development and progression of a variety of tumors including HNSCC, by regulating cell proliferation, cell cycle progression, apoptosis, angiogenesis, immune evasion, Epithelial-Mesenchymal Transition (EMT) and through effects in cancer stem cells. The purpose of this review is to summarize current experimental and clinical evidence that suggests that HNSCC might be addicted to Stat3 and describes the molecular mechanisms that may explain this phenomenon. In addition, we discuss whether this addiction is an exploitable target for developing approaches for the treatment and prevention of HNSCC.

5 March 2019 in Head & Neck
Verified
Journal Article
Closed access
PDF file
RYRyuji Yasumatsu
Ryuji Yasumatsu
TWTakahiro Wakasaki
Takahiro Wakasaki
KHKazuki Hashimoto
Kazuki Hashimoto
KNKoichiro Nakashima
Koichiro Nakashima
TMTomomi Manako
Tomomi Manako
TNTakashi Nakagawa
Takashi Nakagawa

1 February 2020 in Oral Oncology
Verified
Journal Article
Closed access
MMMioko Matsuo
Mioko Matsuo
RYRyuji Yasumatsu
Ryuji Yasumatsu
MMMuneyuki Masuda
Muneyuki Masuda
STSatoshi Toh
Satoshi Toh
TWTakahiro Wakasaki
Takahiro Wakasaki
TNTakashi Nakagawa
Takashi Nakagawa

1 January 2011 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
MMMuneyuki Masuda
Muneyuki Masuda
TWTakahiro Wakasaki
Takahiro Wakasaki
STSatoshi Toh
Satoshi Toh
MSMasahito Shimizu
Masahito Shimizu
SASeiji Adachi
Seiji Adachi
Over the past decade dose-intensified chemo-radiotherapy or molecular targeted therapy has been introduced into the treatments of head and neck squamous cell carcinoma (HNSCC) to improve the outcomes of this dismal disease. However, these strategies have revealed only limited efficacy so far. Moreover, the frequent occurrences of second primary tumor further worsen the prognosis of patients. In this context, early detection and chemoprevention appear to be a realistic and effective method to improve the prognosis as well as quality of life in patients with HNSCC. In this short paper, we discuss the potential of green tea extract, (-)-epigallocatechin-3-galate (EGCG) in HNSCC chemoprevention, focusing on two aspects that are provided recently: (1) evidence of clinical efficacy and (2) unique biological effects on “lipid raft” that emerged as an important platform of numerous biophysical functions, for example, receptor tyrosin kinases (RTKs) signalings including epidermal growth factor receptor (EGFR), which play critical roles in HNSCC carcinogenesis.

4 June 2019 in Annals of Otology, Rhinology & Laryngology
Verified
Journal Article
Closed access
PDF file
TWTakahiro Wakasaki
Takahiro Wakasaki
RYRyuji Yasumatsu
Ryuji Yasumatsu
MMMuneyuki Masuda
Muneyuki Masuda
MMMioko Matsuo
Mioko Matsuo
ATAkihiro Tamae
Akihiro Tamae
TNTakashi Nakagawa
Takashi Nakagawa
Objectives: Small cell carcinomas in extrapulmonary sites (ESmCCs) are very rare. ESmCCs originating in the head and neck account for approximately 10% of all ESmCCs, and there are few reports about this disease. ESmCCs have an aggressive natural history characterized by widespread metastasis. The aim of this study was to investigate the characteristics and outcomes of patients with ESmCCs of the head and neck. Methods: The outcomes of 21 patients with ESmCCs of the head and neck treated between January 2001 and December 2015 at the authors’ hospital and associated facilities were reviewed. Results: There were 18 men and 3 women, and the median age was 74 years (range, 53-91 years). The tumor site was the larynx in 6 patients; the paranasal sinus in 5; the hypopharynx in 3; the oropharynx in 2; the nasopharynx in 2; and the oral cavity, salivary gland, and primary unknown in 1 patient each. The extent of the disease was staged as follows: stage I or II, 3 cases; stage III, 4 cases; stage IVA, 9 cases; stage IVB, 1 case; and stage IVC, 4 cases. The median observation time was 17 months (range, 1-103 months). Four patients (19%) had distant metastasis at initial treatment, and 13 patients (62%) developed distant metastasis within 3 years. Treatments were administered, including radical surgery (9 patients), radiation therapy (5 patients), chemoradiotherapy (7 patients), and chemotherapy (6 patients). The 1- and 3-year overall survival rates of patients were 56% and 37%, respectively. More than half of the patients died of distant metastasis. Conclusions: ESmCCs of the head and neck have a poor prognosis, similar to those of carcinomas in many other sites. Control of distant metastasis would contribute to improving the prognosis of ESmCCs of the head and neck. Further studies are required for better understanding these disease entities and their response to treatment modalities.

1 February 2009 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
STSiamak Jabbarzadeh Tabrizi
Siamak Jabbarzadeh Tabrizi
HNHiroaki Niiro
Hiroaki Niiro
MMMariko Masui
Mariko Masui
GYGoichi Yoshimoto
Goichi Yoshimoto
TITadafumi Iino
Tadafumi Iino
KAKoichi Akashi
Koichi Akashi
BCR signaling plays a critical role in purging the self-reactive repertoire, or in rendering it anergic to establish self-tolerance in the periphery. Differences in self-reactivity between human naive and IgM+ memory B cells may reflect distinct mechanisms by which BCR signaling dictates their survival and death. Here we demonstrate that BCR stimulation protected naive B cells from apoptosis with induction of prosurvival Bcl-2 family proteins, Bcl-xL and Mcl-1, whereas it rather accelerated apoptosis of IgM+ memory B cells by inducing proapoptotic BH3-only protein Bim. We found that BCR-mediated PI3K activation induced the expression of Mcl-1, whereas it inhibited Bim expression in B cells. Phosphorylation of Akt, a downstream molecule of PI3K, was more sustained in naive than IgM+ memory B cells. Abundant expression of T cell leukemia/lymphoma 1 (Tcl1), an Akt coactivator, was found in naive B cells, and enforced expression of Tcl1 induced a high level of Mcl-1 expression, resulting in prolonged B cell survival. In contrast, Galectin-1 (Gal-1) was abundantly expressed in IgM+ memory B cells, and inhibited Akt phosphorylation, leading to Bim up-regulation. Enforced expression of Gal-1 induced accelerated apoptosis in B cells. These results suggest that a unique set of molecules, Tcl1 and Gal-1, defines distinct BCR signaling cascades, dictating survival and death of human naive and IgM+ memory B cells.